Editor,—Following the recent warnings against the use of cisapride in children from the Medicines Control Agency and the Committee on Safety of Medicines (CSM),1 we felt that the recent annotation by Lander and Desai2 was unwise. While it is right to question advice from the CSM, we feel it is more appropriate to do this in a personal practice article, and accompany it with a commentary.

Lander dismisses concerns about cisapride by saying they have not seen abnormalities of QTc in their series of 17 patients, as well as by quoting a study in which only two of 35 patients developed life threatening arrhythmias.3 …